Physical activity may cut Alzheimer's risk | WeForNews | Latest News, Blogs Physical activity may cut Alzheimer’s risk – WeForNews | Latest News, Blogs
Connect with us

Health

Physical activity may cut Alzheimer’s risk

Published

on

Physical activity

Toronto, May 17: Researchers have found that regular exercise may help decrease risk of Alzheimer’s disease, the most common form of dementia, characterised by progressive neurodegeneration that results in memory loss, compromised physical ability and loss of independence.

In a study, published in the journal BMC Public Health, the team of researchers also confirmed that regular physical activity may improve the performance of daily activities for people afflicted with Alzheimer’s.

“As there is no current cure for Alzheimer’s, there is an urgent need for interventions to reduce the risk of developing it and to help manage the symptoms,” said the study first author Kathleen Martin Ginis, Professor at University of British Columbia’s Okanagan campus in Canada.

“After evaluating all the research available, our panel agrees that physical activity is a practical, economical and accessible intervention for both the prevention and management of Alzheimer’s disease and other dementias,” Martin Ginis said.

The researchers reviewed data from more than 150 research articles about the impact of physical activity on people with Alzheimer’s.

Some of the work explored how physical activity improves the patient’s quality of life and the others examined the risk of developing Alzheimer’s based on the amount of activity in which an individual participated.

The panel concluded that regular physical activity improves activities of daily living and mobility in older adults with Alzheimer’s and may improve general cognition and balance.

They also established that older adults not diagnosed with Alzheimer’s who are physically active, were significantly less likely to develop the disease compared to people who were inactive.

“This is exciting work,” Martin Ginis said.

“From here we were able to prepare a consensus statement and messaging which not only has community backing, but is also evidence-based. Now we have the tool to promote the protective benefit of physical activity to older adults. I’m hopeful this will move the needle on this major health concern,” Martin Ginis said.

IANS

Cities

Doctor who managed Goa’s only Covid hospital tests positive

The state currently has more than 900 active Covid-19 cases, with 17 fatalities linked to coronavirus.

Published

on

Dr Gomes

Panaji, July 13 : Dr. Edwin Gomes, who had emerged as the face of Goa”s Covid-19 treatment and care effort, and had served as the in-charge of medication of patients at the state’s only designated Covid-19 hospital, has tested positive for the viral infection, a government spokesperson said.

“Dr. Gomes has been admitted to a state government facility for doctors infected by coronavirus,” the spokesperson said.

Gomes, 58, is also the head of medicine at the state”s only medical college, the Goa Medical College, and had last week ended his unbroken 98-day shift at the designated Covid-19 hospital.

The state currently has more than 900 active Covid-19 cases, with 17 fatalities linked to coronavirus.

Chief Minister Pramod Sawant has said that “four to five” Covid-19 patients who died, were suffering from cancer. “Eight to 10 patients were above the age of 80 years, while one also died of liver failure. The death rate has increased due to co-morbid conditions,” Sawant told reporters at the State Secretariat.

Continue Reading

Disaster

Glenmark cuts Fabiflu price by 27%

On June 20, Glenmark announced that it received manufacturing and marketing approval from India”s drug regulator for FabiFlu, making it the first oral Favipiravir-approved medication in India for the treatment of mild to moderate COVID-19.

Published

on

By

Glenmark Fabiflu

New Delhi, July 13 : Glenmark Pharmaceuticals has announced that it has commenced a Post Marketing Surveillance (PMS) study on FabiFlu to closely monitor the efficacy and safety of the drug in 1000 Covid patients that are prescribed with the oral antiviral.

Further, Glenmark has announced a price reduction of 27 per cent for FabiFlu. The new MRP is Rs 75 per tab from the earlier Rs 103 per tab.

The price reduction has been made possible through benefits gained from higher yields and better scale, as both the API and formulations are made at Glenmark”s facilities in India, the benefits of which are being passed on to patients in the country.

Glenmark has successfully developed the active pharmaceutical ingredient (API) and the formulation for FabiFlu through its own in-house R&D team within the country, ensuring self-reliance with regard to long term production and manufacturing.

Commenting on these developments, Alok Malik, Senior Vice President & Head – India business, Glenmark Pharmaceuticals said, “We expect this post marketing surveillance study to shed more light on the drug”s clinical effectiveness and safety in a large cohort of patients prescribed FabiFlu. Our priority from the start of this pandemic has been to offer patients in India an effective treatment for COVID-19, while also ensuring accessibility to the masses.

“Our internal research shows us that we launched FabiFlu in India at the lowest market cost as compared to the cost of Favipiravir in other countries where it is approved. And now we hope that this further price reduction will make it even more accessible for patients across the country.”

Despite investing significantly in R&D, clinical trials and the manufacturing of FabiFlu (API and formulations), Glenmark has managed to keep the pricing of FabiFlu lower as compared to its price in other countries.

FabiFlu in India was originally launched at Rs 103 per tablet, while, its price in Indian Rupees is higher in the remaining countries like Rs 600 in Russia, Rs 378 in Japan, Rs 350 in Bangladesh and Rs 215 in China.

On June 20, Glenmark announced that it received manufacturing and marketing approval from India”s drug regulator for FabiFlu, making it the first oral Favipiravir-approved medication in India for the treatment of mild to moderate COVID-19.

The manufacturing and marketing approval was granted as part of accelerated approval process, considering the emergency situation of the COVID-19 outbreak in India. The approval”s restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation.

Continue Reading

Disaster

Russia 1st nation to finish human trials for Covid-19 vaccine

There are at least 21 vaccines currently under key trials, according to the World Health Organisation (WHO).

Published

on

Covid 19 Vaccine

Moscow, July 12 : Russia has become the first nation to complete clinical trials of Covid-19 vaccine on humans, and the results have proven the medication’s effectiveness, the media reported on Sunday.

Chief researcher Elena Smolyarchuk, who heads the Center for Clinical Research on Medications at Sechenov University, told Russian news agency TASS on Sunday that the human trials for the vaccine have been completed at the university and they will be discharged soon.

“The research has been completed and it proved that the vaccine is safe. The volunteers will be discharged on July 15 and July 20,” Smolyarchuk was quoted as saying in the report.

There was, however, no further information on when this vaccine would enter commercial production stage.

Russia had allowed clinical trials of two forms of a potential Covid-19 vaccine developed by the Gamaleya National Research Center for Epidemiology and Microbiology on June 18.

The first vaccine, in the form of a solution for intramuscular administration, was carried out at the Burdenko Military Hospital.

Another vaccine, in the form of a powder for the preparation of a solution for intramuscular administration, was carried out at Sechenov First Moscow State Medical University.

The first stage of research on the vaccine at Sechenov University involved a group of 18 volunteers and the second group involved 20 volunteers.

After vaccination, all volunteers were expected to remain in isolation in a hospital for 28 days.

Earlier, results of the COVID-19 vaccine tests performed on a group of volunteers in Russia showed that they were developing immunity to the coronavirus.

“The data obtained by the Gamalei National Research Center for Epidemiology and Microbiology, proves that volunteers of the first and second groups are forming an immune response after injections of the vaccine against the coronavirus,” according to an earlier statement from the Russian Defense Ministry.

Russia has reported 719,449 cases and 11,188 deaths to date.

There are at least 21 vaccines currently under key trials, according to the World Health Organisation (WHO).

The overall number of global COVID-19 cases was nearing 12.7 million, while the deaths have increased to more than 564,000, according to Johns Hopkins University in the US.

As of Sunday morning, the total number of cases stood at 12,681,472, while the fatalities rose to 564,420.

The US accounted for the world’s highest number of infections and fatalities at 3,245,158 and 134,764. Brazil came in the second place with 1,839,850 infections and 71,469 deaths.

Continue Reading
Advertisement

Most Popular